Pale_Rider
-
Posts
127 -
Joined
-
Last visited
Content Type
Forums
Profiles
Store
Gallery
Articles
Blogs
Events
Downloads
Posts posted by Pale_Rider
-
-
Some older news from India. http://www.expresshealthcare.in/200803/market22.shtml
Dr Batra's Clinic to Promote Hair Cloning in India
Thy claim that the success rate of cloning would double that of the standard treatments available nowadays
Dr Batra's Clinic, India's largest chain of homeopathy clinics in India, is in process of working with Prof Dr Rolf Hoffmann, eminent dermatologist and the President of the European Hair Research Society (EHRS).
"The process of hair cloning will bring an answer for hair growth to millions if balding people across the world, particularly women, who have no effective answer to their balding as on date," said Dr Hoffman, known worldwide for inventing the Trichoscan—the world's first ever tool to monitor hair density and measure treatment efficacy. He said that close to 40 per cent of women in their 40's and 50 per cent of women in their 50's experience hair loss.
The procedure of cloning is unique since it's the only one to use the cup cells of the hair to clone and grow new hair. A very small area of hair is taken from the patients scalp. The cells are taken from the cup of these hair follicles, multiplied in a laboratory for three months and then injected onto the balding areas of the patient's scalp.
Prof Dr Hoffmann added that this procedure has so far no potential side effects and that it can re-grow large amounts of hair in a period of two years for people with diffuse hair loss. He estimates the success rate of cloning to double that of the standard treatments available nowadays.
The process of hair cloning is estimated to become a reality for patients in a few years.
Prof Dr Hoffmann indicated his interest in bringing the process to India. He said "The good reputation, number of clinics and the large patient base held by Dr Batra's Clinic makes it a potential partner to bring cloning into India."
Dr Mukesh Batra, Chairman and MD Dr Batra's Clinic, said, "Bringing cloning to India would be an ideal extension of our brand and would be a very good answer for all hair patients in India."
Prof Dr Hoffmann said that the estimated hair care market worldwide is pegged at 150 billion USD. The hair transplant business is estimated to at 1.2 billion USD with an estimated 7,00,000 patients per year visiting a hair transplant surgeon. Prof Dr Hoffmann emphasised the dream of growing multiple hairs from a few donor hair follicles or hair follicle cloning.
EH News Bureau
-
FinHairloss it is about time something new comes out at last. We are in the 21 st century and HT techniques that we have now at our disposal are at least middle age ones, payed by solid gold for poor results. It is a normal thing that human race progresses as years go by. I know that there are lots of HT surgeons that make small fortunes on these primitive methods, and there is also Hollywood promoting youthful looks, who is helping them to make more money on desperate people. But those "doctors" know that their time is coming to the end, so they are bashing everything new that comes out in HM research field. Rassman is one of these people so he tries to make a last push to make enough money for his retirement. After all, he probably lives in the elite part of L.A. so he probably has big life expenses which somebody has to pay. I also think that one day Merck will be sued by many Propecia users for irreversible side-effects that they suffer and will suffer, and lawyers will be rambling each other for that case, yet for it will be a gold mine if Merck looses.
-
Fresh updates from Histogen. http://financewests.com/ears/r12e6517027273n52mi/in9852291033
Histogen Welcomes Dr. Hyma Gollamudi as Chief Business Officer
Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that Dr. Hyma Gollamudi has joined the Company as Chief Business Officer. Gollamudi's business and product development expertise will be invaluable as Histogen begins seeking strategic alliances nationally and internationally.
"With our early-stage product launches underway, and exciting projects coming quickly down the pipeline, Histogen is increasingly examining relationships with companies, physicians and investors," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am excited to welcome Hyma Gollamudi to Histogen, and look forward to seeing the Company's business development and strategic planning efforts flourish through her oversight and experience."
Dr. Gollamudi brings more than 10 years of experience from the healthcare and financial industries to Histogen. Most recently, she served as a Product Director in the healthcare division of Fair Isaac Corporation, a leading provider of analytics and decision management technology. In this position, Dr. Gollamudi oversaw alliances and partnerships and grew the Company's government (Medicare and Medicaid) and commercial business through dedicated attention to client relationships and client managements.
Dr. Gollamudi has authored a number of papers, presented at various healthcare conferences and working groups, and is the co-inventor on two patents. She holds a doctorate in Agricultural Economics from the Ohio State University.
"Histogen's broad range of product applications from a single technology platform is intriguing, and offers almost limitless opportunities in markets from research tools to cosmetics," said Gollamudi. "I am excited to work toward forming alliances, navigating products through reimbursement hurdles, and contributing to the Company's success in various markets."
Through the Company's proprietary bioreactor technology, Histogen is uniquely capable of simulating the embryonic environment, creating products that are embryonic in nature without containing embryonic stem cells or animal components. From two product families - ExCeltrixTM, Histogen's insoluble human Extracellular Matrix (ECM), and ReGenicaTM, Histogen's proprietary liquid complex - the Company has created a product portfolio which includes applications from stem cell culturing to skin care, tissue regeneration to hair regrowth.
About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high-value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen recently launched its first product - BioNuesisTM Human Stem Cell Culturing Kits - and announced the creation of its cosmeceutical venture - Histogen Aesthetics. For more information, please visit http://www.histogeninc.com.
Author Information
Eileen Naughton Brandt
May 10th, 2010
-
Another fresh updates from Aderans. They are pumping those articles these days aren?t they? http://www.prweb.com/releases/Investigative/Dermatology/prweb3971924.htm
Aderans Research Presents at SID (Society of Investigative Dermatology)Aderans Research Institute Inc. (ARI) this week presents an abstract at the prestigious Society of Investigative Dermatology (SID) at the society’s annual meeting in Atlanta.
Atlanta, GA (PRWEB) May 7, 2010 -- Aderans Research Institute Inc. (ARI) this week presents an abstract at the prestigious Society of Investigative Dermatology (SID) at the society’s annual meeting in Atlanta.
The abstract—entered in the “Hair and Cutaneous Development” category—concerns hair follicle formation from cultured cells, and summarizes research conducted by a group of ARI researchers, including ARI research scientist Arben Nace, Executive Vice President Ken Washenik M.D., Ph.D., and Kurt Stenn M.D., Vice President Research and Chief Scientific Officer. Entitled, “Common mechanism of hair follicle formation from dissociated trichogenic epidermal and dermal cells,” the work investigates whether morphogenetic steps dissociated cells take to produce a hair follicle in a mouse are the same across all mammals. The study concludes, “that hair follicles form from dissociated cells in all mammals by one common, or universal, morphogenetic pathway.”
“This abstract covers important ground in our research into follicle formation and activity,” said Ken Washenik. “It is central to our efforts to develop a clinically viable answer to the challenge of hair regeneration.”
“Presenting at SID is always an honor,” added Kurt Stenn. “It lends a degree of credibility to your work and provides a level of exposure you won’t find anywhere else.”
The 2010 SID Annual Meeting takes place May 5-8 at the Hilton Atlanta Hotel in Atlanta, GA.
About the SID
The Society of Investigative Dermatology is one of the leading organizations devoted to cutaneous investigation. Its stated mission is “to advance and promote the sciences relevant to skin health and disease through education, advocacy, and scholarly exchange of scientific information.” The society produces the Journal of Investigative Dermatology (JID), the premier journal dedicated to basic and clinical research in cutaneous biology. Learn more at http://www.sidnet.org
About Aderans Research
Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.
More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://www.aderansresearch.com/ari_clinicupdates.html
Additional information on ARI can be found at www.aderansresearch.com.
Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company
Another important .pdf file...
COMMON MECHANISM OF HAIR FOLLICLE FORMATION FROM DISSOCIATED TRICHOGENIC EPIDERMAL AND DERMAL CELLS
-
Fresh updates from Aderans. http://www.mynewsdesk.com/us/view/pressrelease/aderans-research-aderans-research-expands-clinical-studies-404413
General News US
Aderans Research: Aderans Research Expands Clinical Studies
May 04, 2010 13:30 CEST
Aderans Research Institute Inc. (ARI) said today it has expanded its clinical trials on hair regeneration by an additional seven cities in the United States. Las Vegas, NV; Los Angeles, CA; and New Hyde Park, NY, have been added through clinical site company Impact Clinical Trials. Tucson, AZ; St. Louis, MO; Birmingham, AL; and St. Petersburg, FL, have been added through clinical site company Radiant Research.
Collectively, the Radiant and Impact sites will add around 80 new subjects to the study. Combined with at least twenty new additions at a site hosted by TKL Research, the second phase of ARI’s clinical study will surpass 200 subjects in total, a remarkable number of participants for a Phase 2 trial.
“The expansion of our study reflects not only the significance of the investment made by Aderans Co. Ltd of Japan, but also our confidence that we’re getting closer to a commercial viable solution to the problems of hair loss,” said Vern Liebmann, Vice President, Operations.
Added ARI Executive Vice President Ken Washenik M.D., Ph.D., “We’ve received some encouraging results from our initial Phase 2 studies and we’re eager to expand the trial, add new protocols, and refine our knowledge of the hair multiplication and regeneration process.”
Kurt Stenn M.D., Vice President of Research and Chief Scientific Officer, commented, “It is gratifying to see our research being steadily confirmed in our clinical work.”
Phase 2 launched in November of 2008. Phase 1 of ARI’s clinical study began in September of 2006 and concluded in February of 2008.
About Aderans Research
Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd., the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.
More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visithttp://www.aderansresearch.com/ari_clinicupdates.html
Additional information on ARI can be found at www.aderansresearch.com.
Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/
-
Hahaha, FinHairLoss that first one was mine question. That guy is totally pessimistic about future hair loss treatments for about 20 years. But here are some fresh updates form Histogen. http://www.prweb.com/releases/2010/05/prweb3953054.htm
-
Histogen updates: http://www.prweb.com/releases/2010/05/prweb3953054.htm
Hypoxia Induces Stem Cell Gene Expression, Protein Production and Cell Surface Markers
Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present new findings today at the International Conference on Stem Cell Engineering (ICSCE). Analysis of the cells grown under Histogen's proprietary conditions of hypoxia and low gravity show the expression of specific markers associated with embryonic stem cells.
San Diego, CA (PRWEB) May 3, 2010 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present new findings today at the International Conference on Stem Cell Engineering (ICSCE). Analysis of the cells grown under Histogen's proprietary conditions of hypoxia and low gravity show the expression of specific markers associated with embryonic stem cells.
Different cell types can be identified by unique profiles based on the genes they express, the proteins they produce, and markers that they have on their cell surface. Histogen has discovered that, under growth conditions of 2-5% oxygen (hypoxia) and low gravity, safe and non-controversial newborn skin cells (fibroblasts) acquire the profile of pluripotent stem cells.
Induction of Stem Cell Marker Expression in Human Dermal Fibroblasts in Hypoxic Culture Conditions 
"Over 5,000 genes are differentially expressed by these cells, as compared to fibroblasts grown under traditional conditions," said Dr. Gail K. Naughton, CEO and Chairman of the Board at Histogen. "What we are seeing is a shift in the profile of these cells to one that is more embryonic-like, more similar to stem cells than fibroblasts." DNA microarray analysis revealed that, under hypoxic culture conditions, fibroblasts upregulate the expression of key embryonic stem cell markers including Oct4, Nanog, and Sox2. These specific genes are known to be critical in the generation of induced pluripotent stem cells. A number of other stem cell-associated markers, such as Brachyury, Gata4, CCR4, LIN28 and Nodal FGF5 were also expressed at higher levels in the hypoxic cultures as compared to fibroblasts grown under normal oxygen levels.
These studies suggest hypoxic culture of somatic cells in large-scale bioreactor systems is a potentially feasible and efficient method for obtaining and producing adequate amounts of pluripotent stem cells and associated factors for clinical regenerative medicine applications.
"Reprogramming adult, differentiated somatic cell types through chemical manipulation or genetic transfection to transform the cells into a dedifferentiated, pluripotent stem cell phenotype has been the focus of many recent studies," said Dr. Jonathan Mansbridge, Chief Scientific Officer at Histogen. "Although these experiments have demonstrated the ability to induce cells back to a pluripotent state, the methods used have raised considerable issues regarding mutagenicity and clinical safety. We now have preliminary evidence that, by altering the oxygen levels under which neonatal fibroblasts are cultured, there is potential for a viable pluripotent stem cell source that would be free of these issues."
Human extracellular matrix (hECM) compositions produced under the hypoxia/microgravity conditions discussed here are covered by pending US patent #2010/0047305. "Induction of Stem Cell Marker Expression in Human Dermal Fibroblasts in Hypoxic Culture Conditions" will be presented by Dr. Mansbridge at the ICSCE event, taking place May 2-5, 2010 in Boston, Mass.
About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. For more information, please visit http://www.histogen.com.
-
Remember that famous Dr. Angela Christiano(famous dr. Colin Jahoda??s coworker)? Read this and comment please. http://www.webmd.com/skin-prob...fifed?src=RSS_PUBLIC
-
Another update from Histogen, video format. Dated Nov. 17th 2009
-
Updates from Histogen... http://www.sddt.com/news/artic...urceCode=20091029crd
-
Originally posted by KeepingWhatIHave:
Well absolutely. Though look at newborn babies. It can take five years for a newborn to have thick growing hair. You rarely see a little boy or girl under 3 with full hair, even though the new hair follicles are there and still forming.
That is true. A lot of money is being spent for this research and our fortune in this misery i that Bosley is greedy for money and they will not let anyone else to take "their" market. Cold war has its own advantages sometimes.
-
I??ve read somewhere about that and I think that the results of those big trials will be evident by the end of 2009. 8 months is more than enough time to see if those trials are going somewhere or not.
-
Originally posted by KeepingWhatIHave:
This is... interesting... or am I missing something here?
New generation of snake oils and scams.
-
Only real chance fpr now or at least close to real is Histogen. Intercytex is going bankrupt http://www.intercytex.com/icx/...ses/2009/2009-09-02/ and Aderans will post an update before the end of this year on those April human trials. I must say I am disappointed in human technology. This problem is here since day 1 human walked this Earth and yet no solution whatsoever, shame.
-
Originally posted by KeepingWhatIHave:
Yes, there are tons of companies trying to cure it, but it seems only a few are on the right track.
And how does Histogen differ from Follica and Aderans? They look to be pretty much the same thing upon reading some articles. Either way, I hope their trials are going well... they can already grow some hair on bare scalp, it's just a matter of time before they can make some adjustments, fix some small problems, have successful trials and make this available.
Fingers, legs and eyes crossed!
Like I have said, who works makes mistakes. Mistakes are good because everybody are learning from it and chances for a successful treatment are greater and greater. No one didn??t do anything like this before and that??s why we shall see the treatment.
-
Well more and more scientists in the world are trying to cure baldness because that project will bring tons of money needed maybe for some other projects, it is not USA only who is developing baldness treatments, many more companies in the world are working on it too. Every year more and more baldness genes are found and that means that one day we will have an absolute cure for baldness called gene therapy. Today modern science is going faster than ever, we have the equipment that is far more advanced than anything else before. I think that that Histogen wnt treatment will be a good solution but Follica or Aderans will make a home-run. I know that some were talking about baldness cure before but no one actually did some good research with human trials like they do now. Who works makes mistakes and eventually they will find a solution. Personally I think that we will see a good treatment before a full decade. Good baldness treatment is a golden mine and there is a real "cold war" going on between research companies.
-
Originally posted by KeepingWhatIHave:
Oh wow... I could gladly part with 10k for a full head of hair... I know someone who's spent 20k on a bad HT.
Please, let this get passed soon!
I am 1000% absolutely sure that in 10 years tops we will have solutions that will change our lives. I know that pessimism is present and that is being spread by dishonest HT and "snake oil" salesmen, soon they will all be out on the street where they belong and they know it so they are trying to make a last push for their products.
-
Originally posted by KeepingWhatIHave:
Anyone else think, even if the technology breaks through and something that regrows new hair comes along, it will be ridiculously expensive and only a select few will be able to get it done? =P
At any rate, I'm very excited to see the progression of Histogen... this is pretty cool news.
Talk was about that and the biggest price was said $10.000 a head from Aderans HM, and that is not yet defined. Sure it will be expensive but it will be affordable for the most. Real business is made selling it to the wider population not just the rich ones. What matters the most is hope that this really expensive, primitive and noneffective approach that we have now will perish away sooner than later.
-
Originally posted by brentipold:
2015 is still pretty far off.
2015 is for U.S. market my friend, FDA is your main reason why you will not have it sooner. Other countries don??t have restrictions as U.S. does and they will enjoy the cure sooner so that if that means traveling it is fine by me. Dakota it is 5 years 4 months to go.
Aderans phase II should be over by the end of 2009 so we should hear about them too, they are pumping some serious money into their project. Let??s keep our fingers crossed.
-
Here is Dr. Gail Naughton interview on ReGenica. I??ve would say very good news. Comment please.(interview starts at the acrobat reader page 8 or 120 at scaned newspapers) http://www.ishrs.org/PDF/F4-2009.pdf
Latest Histogen Regenica updates... http://www.histogeninc.com/aboutus/news_events.htm
-
Has anyone tried any of the two or a combo??? I??ve heard that some people had excellent results with DMSO... Give your 2c...
-
don??t be a pessimist that is an easier obstacle getting hair grow is the real deal...
-
2008 has passed and there is no update from Intercytex... Bad...
-
Originally posted by Chuckisduck:
That is pretty much true. Being tall and having full hair will always help, but you can get a good girl and be short and bald. I am 6'2" and most girls find me attractive, but 3 years ago I was really depressed after a long relationship that ended. I have had girls now tell me that I was hot, but they weren't interested cause I was all mopey then.
Pale Rider, I ended up asking my grandmother abotu the Croatian side of the family. The only thing she told me is that one of the families is from around Majagorie. I think its gonna be hard to find out anything more, and I think the reference to Majagorie is that she is very religious.
Of course it is true. If you suck with women without hair you will suck with hair, it is purely personality, and that can be changed if you have the will. There are shallow people everywhere but that is a sign that they have complex problems of their own and deeply inside they are miserable themselves, personally I don??t want to be with that kind of a woman. I am sorry about your relationship, I believe we are all been there but after a rain always comes the sun, that is mine philosophy.
About your origin your grandmother is probably from Medjugorje(Me?‘ugorje), today that is in Bosnia&Herzegovina, today the town is best known due to reported apparitions of the Blessed Virgin Mary which appeared to six Herzegovinian Croats since 24 June 1981, and is now visited by pilgrims from around the entire world as a shrine. You can read more here if you are interested http://medjugorje.hr.nt4.ims.h...spx?mv=4&qp=MToxOjE=
Movie "Gospa" was made about it, Martin Sheen played a major role, Michael York played too. http://www.imdb.com/title/tt0113200/
Aderans is looking for participants for its phase II
in Future Medical treatments
Posted
It is good though that the donor hair is unlimited but the price will be probably double as it is now on FUE, "Unfortunately, the procedure is very labor intensive and will compound the already high cost of hair transplants, so this may be out of reach for the average baldie (Gho is rumored to have worked on an increasing number of Dutch celebrities)." they say. Good job Gho but still very primitive and unacceptable.